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Background Since the release in Thailand in 2001 of the Third Guidelines by 
the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation and Treatment of High Blood Cholesterol in Adults or the Adult 
Treatment Panel (ATP III), there have been no nationwide studies on the propor-
tion of dyslipidaemic patients who have achieved the low-density lipoprotein 
cholesterol (LDL-C) goals. The authors therefore aimed to estimate the percentage 
achievement of LDL-C goals based on the modified NCEP ATP III guidelines in 
intermediate- to high-risk patients. Methods The authors conducted a hospital-
based, cross-sectional, epidemiological survey. Patients (1240) were selected 
consecutively from 50 hospitals across Thailand. Patients were included if they had 
been treated with statins for at least 3 months. Results Two-thirds were female, 
and the mean age was 61.7+69.5 years. The median duration of statin treatment 
was 21 months. Half (633/1240) of the patients achieved the LDL-C goal levels as 
defined by the NCEP guidelines (51.1%, 95% CI 48.3% to 53.8%). The very high-
risk group had the lowest percentage achievement (11.6%; 95% CI 1.6% to 21.6%), 
compared with 54.2% (95% CI 50.9% to 57.4%) for the high-risk group and 47.0% 
(95% CI 41.1% to 52.8%) for the moderate-risk group. More males achieved the 
LDL-C goals than females (55.6% vs. 48.9%; P = 0.029). Conclusions Overall, 51.1% 
of the patients with cardiovascular risk, on statins treatment, achieved the NCEP 
ATP III LDL-C goal levels.
Keywords: dyslipidemia, goal attainment, Thailand
1. Introduction
Dyslipidemia is a major risk factor for the development of atherosclerotic dis-
ease. Therefore, lifestyle interventions and pharmacological approaches to decrease 
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cholesterol are widely used in cardiovascular disease prevention. The introduction 
and widespread use of 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) 
for individuals at risk of atherosclerotic disease has been an important advance in 
cardiovascular care [1].
Since 1993, the National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel or ATP) has periodically updated the treatment guidelines 
which identify LDL-C as a cause of CHD and the primary aim for diagnosis and 
treatment of hypercholesterolaemia [1–3].
In 2001, the recommendations were released in the Third ATP Report (NCEP 
ATP III) [3] which reaffirmed the risk of CHD from increased LDL-C, the benefit 
of LDL-C-lowering therapy and maintaining intensive treatment of patients with 
CHD. The report also added a call for more intensive LDL-C-lowering therapy as 
the primary aim for patients with a CHD risk equivalent.
There can be no doubt that better control of dyslipidemia, even in subjects 
whose low-density lipoprotein cholesterol level is not particularly high, has reduced 
overall event rates. On a background of lifestyle interventions, statins are routinely 
used to decrease risk along with aspirin and interventions to control hypertension 
and diabetes. The efficacy of statins in atherosclerotic conditions, particularly in 
the treatment and prevention of CHD, has been well established [4]. Large-scale, 
randomized, prospective trials involving patients with CHD have shown that statins 
reduce the clinical consequences of atherosclerosis, including cardiovascular-
related deaths, non-fatal MI and stroke, hospitalization for acute coronary syn-
drome and heart failure, as well as the need for coronary revascularization [5–7].
2. Clinical practice
Although the guidelines have been widely available, achieving the lower 
LDL-C goals in practice has been suboptimal. In a US study, only 38% of 4888 
patients under primary care in five regions achieved the LDL-C target levels [8]. 
The respective success rates were 68% and 37% in the low- and high-risk groups. 
Only 18% of the patients with established CHD with the highest risk of future 
CHD events achieved the lower LDL-C targets. Another study, based on the 
records of 461 patients in rural areas, covering all risk levels from four practices, 
found that only 54% of dyslipidaemic patients achieved the NCEP ATP III goals 
[9]. In 1998, a survey in Thailand assessing the achievement of LDL-C goals in 
high-risk patients indicated an unsatisfactorily low percentage of 39.2% [10]. The 
most recent nationwide survey was conducted between December 2002 and June 
2003 [11]. The study involved 1921 patients from 48 hospitals across Thailand. 
Percentage achievements of LDL-C targets in the CHD and CHD equivalents, 
high-, and low-risk group were 34.6, 56.4 and 76.8%, respectively [11]. In 2004, 
several changes were made to the guideline, released as the Modified NCEP ATP 
III in that year [12]. There has, however, been no recent nationwide study in 
Thailand investigating the proportion of dyslipidemia patients who have achieved 
the updated LDL-C goals.
3. Clinical practice in Thailand
In our study [13], we conducted a hospital-based, cross-sectional, epidemiologi-
cal survey and retrospective chart review, in both secondary and tertiary care across 
Thailand. Our study aimed to estimate the percentage of LDL-C goals achievement 
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based on the NCEP ATP III guidelines in intermediate- to high-risk patients receiv-
ing statins for at least 3 months in clinical practice in Thailand. The data collection 
was conducted at the selected hospitals between March and July 2008. The primary 
outcome of this study was the percentage of dyslipidaemic patients on lipid-lower-
ing therapy who had achieved their respective LDL-C target levels as defined by the 
NCEP ATP III guidelines.
3.1 Number of patients and participating hospitals
There are 95 secondary- and tertiary-care hospitals across Thailand, 50 (52.6%) 
of which were selected for the study. The number of selected hospitals in each 
region was proportional to the total number of eligible hospitals in each region (i.e., 
the North, the Northeast, the South and Central). A total of 1730 patients attending 
OPD clinics were screened by interviews, and 167 (9.6%) were excluded: 161 not 
currently treated with statin, five not consented and one not within 20–80 years 
of age. After the chart review was conducted, a further 323 (20.7%) cases were 
excluded: 216 treated <3 months before lipid profile became available, 32 lipid 
profile not available and 75 having not received the same statin before lipid profile 
became available.
The duration of statin treatment prior to the date of the most recent lipid profile 
ranged between 3 and 191 months (median 21 months), which represented the 
period of statin treatment at the time of assessing the treatment outcome.
The high-risk group accounted for the largest number of patients, followed 
by moderate- and high-risk patient types. The mean age was 61.7 ± 9.5 years, and 
approximately two-thirds were female. The mean age of each risk group was similar. 
Overall, the majority of males at risk (94%) were 45 years of age or higher. A similar 
percentage was seen in each risk group. For females at risk, about three-quarters 
were aged 55 years or older. Most common cardiovascular risks were diabetes mel-
litus (66.1%) and hypertension (57.6%).
3.2 Percentage achievement of LDL-C goals for all patients
Among the 1240 patients, 633 achieved the lower LDL-C goals as defined by 
the NCEP ATP III guidelines (51.1%; 95% CI 48.3% to 53.8%) (Table 1). The very 
high-risk group had the lowest achievement level at about one tenth. The achieve-
ment rate varies among regions where the highest achievement rate was 57.4% in the 
central area, and the lowest achievement rate was 42.6% in the eastern part of the 
country. On average, the very high-risk patients were about half, 49.7%, to reach  
the LDL-C target goal.
Patient groups* Total Achieved goals Percentage 95% CI Mean percentage† to target 
LDL-C
Very high risk 43 5 11.6 1.6 to 21.6 49.7
High risk 914 495 54.2 50.9 to 57.4 31.8
Moderate risk 283 133 47.0 41.1 to 52.8 9.9
Overall 1240 633 51.1 48.3 to 53.8 27.5
*Very high risk (LDL-C < 70 mg/dl); high risk (LDL-C < 100 mg/dl); moderate risk (LDL-C < 130 mg/dl).
†Calculated based on the percentage difference between LDL-C level and the target goal among patients who did not 
achieve the LDL-C target.
Table 1. 
Percentage and 95% CIs of low-density lipoprotein cholesterol (LDL-C) achievement goals by patient group.
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Males had a statistically higher percentage achievement of the lower LDL-C 
goals than females (p = 0.024) (Table 1). The duration of statin treatment and the 
statin use, either alone or combined with other regimens, had a similar percentage 
achievement of lower LDL-C goals.
The final number of subjects included in the analysis was 1240. Initially, the cal-
culated sample size was 1260, of which 20 (1.8%) patients had a statin treatment of 
<3 months. These were identified after enrolment and excluded from the analysis. 
This elimination did not, however, affect the study findings, that is, the percentage 
achievement of LDL-C goals was 52.5% when they were included, compared with 
51.1% when they were excluded.
We, thus, included only patients who had been treated for at least 3 months with 
no maximum limit of treatment duration. The results in Table 2 indeed suggest 
that the duration of statin treatment had no effect on the percentage achievement 
of LDL-C goals, which was about 51% for every interval of 12 months (p = 0.975). 
Selected factors No Percentage achievement p Value
Gender 0.029
 Male 417 55.4
 Female 823 48.9
Male by age (years) at risk 0.750
 ≥45 394 55.6
 <45 23 52.2
Female by age (years) at risk 0.057
 ≥55 of age 623 50.7
 <55 200 43.0
Duration (months) of statin treatment 0.997
 3–6 136 50.7
 7–12 245 51.0
 13–24 349 50.4
 25–36 235 51.9
 ≥37 275 51.3
Statins received 0.842
 Statins only 1156 51.1
 Statins with other lipid-lowering drugs 84 50.0
Field of expertise of attending physicians 0.360
 Internal medicine 1227 51.2
 Non-internal medicine 13 38.5
Field of expertise of attending physicians  
who were in internal medicine
0.598
 General 1029 51.2
 Cardiologist 128 53.9
 Endocrinologist, nephrologists or neurologist 67 46.3
Table 2. 
Percentage low-density lipoprotein cholesterol achievement goals by selected factors.
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However, there are numerous factors which may confound the goal achievement, 
including statin dose, potency of statin, culture, socio-economic status, healthcare 
policy, concomitant medications, etc. Also, the selection bias from selected study 
sites, which were from diabetes and hypertension clinics even we tried to do the 
study in various parts of the country. This leads to a higher proportion of high-risk 
group than general populations.
Our study was based on the availability of lipid profiles of patients measured 
on request, as per real-life clinical practice; however, there were no significant 
differences between the percentage achievement of LDL-C goals among patients 
whose lipid profile was assessed before or after the median of 5.5 months prior to 
the survey date. This result might indicate that LDL-C levels were underutilized to 
adjust the treatment.
In our study, the percentage of lowered LDL-C according to goal levels, as 
defined by NCEP ATP III guidelines, among the high-cardiovascular-risk group, 
was 51.1% compared with 39.2% in a 1997–1998 study [10] and 34.6% in the 
2002–2003 study [14]. The higher percentage found in our study could be due to 
various reasons: (1) we included only patients who used statins and not any other 
lipid-lowering agent alone; (2) there has been an increasing focus on the benefits 
of intensive cholesterol reduction; (3) new and more efficacious statins have been 
developed; (4) 95% of the patients in our study were attended by specialists who 
might be more likely to adhere to the guidelines; and (5) two-thirds of the patients 
in our study were females, who might have had a greater rate of compliance to the 
treatment or might have had a greater response to therapy than males, although 
there are few data to support this. As with other studies, our study found that the 
lowest percentage of achieving the recommended LDL-C target was in the very 
high-risk group [10, 14].
A number of aspects of our study can be considered strengths. First, the case 
selection was unbiased, as it was carried out consecutively and independent of 
the attending physicians. Second, we covered a large number (52.6%) of second-
ary- and tertiary-care hospitals across the country. Third, almost all of the studied 
patients (99.0%) were attended by an internal medicine, specialist, particularly 
the very high-risk and high-risk patients. Finally, our study represented real-life, 
clinical settings in Thailand, so the percentage achievement of LDL-C goals may 
represent clinical practice.
In summary, our study demonstrated that 51.1% of patients with cardiovascular 
risk on statin treatment achieved the LDL-C goal levels defined by the NCEP ATP 
III guidelines. We suggest that patients with a high CHD risk should be targeted for 
more aggressive lipid-lowering management. National campaigns to increase the 
awareness among both physicians and patients of the importance of achieving the 
LDL-C goals are needed to optimize the prevention of cardiovascular events and 
to further reduce the burden of cardiovascular diseases. Further investigation is 
needed to understand the reasons for patients not achieving lower LDL-C levels.
4. Clinical implications in real world practice
Despite the >50% decrease in age-adjusted cardiovascular mortality over the 
past several decades, atherosclerotic disease is still the leading cause of morbidity 
and mortality. Moreover, cardiovascular disease accounts for more than half of all 
non-communicable diseases and has become the leading cause of death worldwide, 
a fact affirmed by the World Health Organization [15]. Large cohort studies dating 
back to the Framingham Heart Study have identified cholesterol as a modifiable 
risk factor, which can be treated with lifestyle and pharmacological interventions 
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[16]. Total cholesterol levels have decreased in high-income countries over the past 
2 decades by 8–10% on average. Some countries with the highest levels were able to 
decrease levels more than this with targeted societal interventions, leading directly 
to dramatic decreases in event rates. As part of the United Nations declaration on 
non-communicable diseases, with a goal of reducing premature death by 25%, their 
target is a 20% relative reduction in high total cholesterol by 2025. To be truly effec-
tive, the treatment of dyslipidemia needs to be incorporated into a comprehensive 
plan of global risk reduction for patients at risk. This will involve lifestyle modifica-
tion, policy change, and pharmacotherapy.
5. Similarities and differences in dyslipidemia guidelines
New dyslipidemia guidelines were released by the European Society of 
Cardiology (ESC)/European Atherosclerosis Society (EAS) in 2011 [17], the CCS 
in 2012 [18], the International Atherosclerosis Society [19], and the American 
College of Cardiology (ACC)/American Heart Association (AHA), both in 2013 
[20]. All are similar in many respects, yet have some key differences that are worthy 
of discussion. The 2012 CCS guidelines recommended risk stratification using the 
total cardiovascular disease Framingham Risk Score (FRS) [21], advocated the 
use of low-density lipoprotein cholesterol (LDL-C) thresholds for the initiation 
of treatment in low- and intermediate-risk subjects and expanded the phenotype 
of high-risk subjects to include subjects with atherosclerosis, most patients with 
diabetes, high-risk hypertension (per Anglo-Scandinavian Cardiac Outcomes Trial 
[ASCOT] inclusion criteria) [22] and predialysis chronic kidney disease (CKD). 
LDL-C continues to be used as the atherogenic metric, but now non-high-density 
lipoprotein cholesterol (HDL-C) and apolipoprotein B (apo B) could be measured 
as alternatives, especially under circumstances when LDL-C calculations are 
known to be erroneous. When treatment is initiated, LDL-C (<2.0 mmol/L or 50% 
reduction) continues to be the primary target of therapy. The CCS guidelines have 
been harmonized with other relevant Canadian guidelines as part of the Canadian 
Cardiovascular Harmonization National Guidelines Endeavor (C-CHANGE) initia-
tive [23] (Table 3).
The ESC/EAS guidelines was a comprehensive document that encouraged the 
use of the Systematic Coronary Risk Evaluation (SCORE) total cardiovascular 
mortality [24].
Calibrated for high- or low-risk countries in Europe. Of note, the SCORE risk 
assessment is also based on the Framingham risk equation. LDL-C thresholds were 
suggested with non-HDL-C or apo B as alternatives. The European guidelines also 
recognized CKD as very high-risk equivalent. Target levels of LDL-C were recom-
mended but unlike the CCS guidelines, the goals were different between those at 
very high risk (<1.8 mmol/L) compared with those at high risk (<2.5 mmol/L) or 
intermediate risk (<3.0 mmol/L).
The International Atherosclerosis Society panel decided to recommend lifetime 
cardiovascular risk based on 4 different tools depending on ethnicity. They favored 
non-HDL-C as the primary atherogenic metric for risk determination, with LDL-C 
as a secondary measure. Optimal levels were defined based on criteria from Adult 
Treatment Panel-III (ATP-III), but did not recommend treatment targets. The 
intensity of statin therapy should be adjusted according to overall lifetime risk and 
practitioner practice.
The ACC/AHA guidelines were the latest to be released and created the most 
controversy [20]. A major novel aspect of these guidelines was the recommendation 
to calculate risk using the newly developed Pooled Cohort Equation. This approach 
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represents a departure from the use of the FRS, used for decades. Of the 4 groups 
targeted for statin-based therapy, 3 were the same as the CCS guidelines. These 
include subjects with: (1) clinical evidence of atherosclerosis; (2) most subjects 
with diabetes; and (3) individuals with LDL-C ≥5.0 mmol/L. The fourth group 
includes subjects with a 10-year risk of total atherosclerotic events calculated using 
the Pooled Cohort Equation of ≥7.5% [25, 26]. There was no specific recommen-
dation for CKD and other populations such as genetic dyslipidemia or high-risk 
hypertension. An additional novel aspect of these guidelines was the lack of spe-
cific targets of therapy. Although these guidelines recommend the use of high- or 
moderate-intensity statin regimens based on level of risk and anticipate a 50% 
LDL-C decrease with high-intensity statin therapy, there is no recommendation 
for treating to any specific target. Therefore, lipid measurements after initiation of 
statin therapy are recommended, primarily to ensure adherence.
6. The elimination of atherogenic lipoprotein targets
The new ACC/AHA guidelines were distinctly different from most previous 
recommendations in that they have discarded specific LDL-C (or alternative) targets 
when subjects are initiated with therapy. The rationale for this change was that no 
previous randomized trial specifically addressed whether a particular level produced 





(EAS) in 2011 [17]
2011 Comprehensive document that 
encouraged the use of the Systematic 
Coronary Risk Evaluation (SCORE) total 
cardiovascular mortality 10 calibrated 
for high- or low-risk countries in Europe. 
Also recognized CKD as very high-risk 
equivalent
Target levels of LDL-C were 
recommended but unlike the CCS 
guidelines, the goals were different 
between those at very high risk 
(<1.8 mmol/L) compared with 
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cardiovascular disease Framingham Risk 
Score (FRS), use of LDL-C thresholds 
for the initiation of treatment in low- and 
intermediate-risk subjects and expanded 
the phenotype of high-risk subjects to 
include subjects with atherosclerosis, 
most patients with diabetes, high-risk 
hypertension
LDL-C continues to be used as the 
atherogenic metric, but non-high-
density lipoprotein cholesterol 
(HDL-C) and apolipoprotein B 
(apo B) could be measured as 
alternatives, especially under 
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2013 Recommend lifetime cardiovascular risk 
based on 4 different tools depending 
on ethnicity. They favored non-HDL-C 
as the primary atherogenic metric for 
risk determination, with LDL-C as a 
secondary measure. Optimal levels were 
defined based on criteria from Adult 
Treatment Panel-III (ATP-III)
Not recommend treatment targets. 
The intensity of statin therapy 
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2013 Recommendation to calculate risk using 
the newly developed Pooled Cohort 
Equation. No recommendation for 
treating to any specific target. “Fire and 
forget” approach
Created the most controversy. Novel 
aspect was the recommendation 
to calculate risk using the newly 
developed Pooled Cohort Equation. 
The new risk engine tended to 
overestimate events.
Table 3. 
Similarities and differences in dyslipidemia guidelines.
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greater event reduction. Second, by eliminating targets it was believed that primary 
care treatment would be more straightforward and easier to implement. Third, hav-
ing targets potentially promotes combination therapy, for which there is currently no 
good evidence from randomized trials. This is supported by data from meta-analysis 
of trials of fibrate therapy, Atherothrombosis Intervention in Metabolic Syndrome 
with Low HDL/High triglycerides and Impact on Global Health Outcomes (AIM-
HIGH) and Heart Protection Study 2: Treatment of HDL to Reduce the Incidence 
of Vascular Events (HPS2-THRIVE) [27–29].When using combination therapy one 
must be aware that the addition of either fibrates or niacin to statin therapy may 
increase the risk of myositis. The increased risk of myositis is greatest when gemfi-
brozil is used in combination with statins. Fenofibrate has a much more modest risk 
and the FDA approved the use of fenofibrate in combination with moderate doses 
of statins. The increased risk with niacin appears to be modest. In the AIM-HIGH 
trial the risk of myositis was not increased in patients on the combination of Niaspan 
and statin, whereas in the HPS2-Thrive trial myopathy was increased in the group 
treated with the combination of niacin and statin. The absolute risks of combination 
therapy are relatively modest if patients are carefully selected; in many patients at 
high risk for cardiovascular disease combination therapy may be appropriate. As 
with many decisions in medicine one needs to balance the benefits of therapy with 
the risks of therapy and determine for the individual patient the best approach. In 
deciding to use combination therapy a key focus is the non-HDL-C level. When the 
LDL is at goal but the non-HDL-C is still markedly above goal it may be appropriate 
to resort to combination therapy in patients at high risk.
Although this interpretation is literally correct, it fails to recognize several issues 
in the history of statin trials: the initial trials were as much studies of the lipid 
hypothesis as they were trials of statins. Thus, the first trials were in patients with 
the highest risk and highest cholesterol levels but at a time when only moderately 
potent statins were available, hence the use of the highest dose feasible. Because 
success was shown, and as more potent statins became available, ethical consider-
ations mandated that research subjects had to have lower and lower risk and lower 
and lower cholesterol levels, again promoting use of the highest available dose. 
The latter was also influenced by a need to ensure simplicity in large trials and, to 
some extent, by marketing designed to promote drug potency differences. There 
are also 5 trials of higher vs. lower potency statins, which show consistent improve-
ment in outcomes with the higher potency statin. The lowest risk cohort studied 
to date in the Justification for the Use of Statins in Prevention: An Intervention 
Trial Evaluating Rosuvastatin (JUPITER) study reaped comparable benefit using 
the most potent statin currently available. Remarkably, no lower limit of achieved 
LDL-C beyond which benefit is accrued has yet been shown. The CCS dyslipidemia 
guideline primary panel reviewed these issues in early 2014 and recommended 
that until further evidence was available, we would continue to support the use of 
targets. Although it is certainly true that randomized trials have generally used a 
single statin dose approach, as opposed to a target LDL-C level, the epidemiology 
suggesting that lower levels of achieved LDL-C result in less events is rather com-
pelling. Also, regression studies with intravascular ultrasound demonstrate a linear 
relationship between LDL-C and the amount of regression [30]. The crossing point 
for regression tends to occur at an LDL-C of around 2 mmol/L or a 50% reduc-
tion. A very recent meta-analysis used individual patient data from 8 statin trials 
[31]. Using a fixed dose of statin, there was a very large inter-individual variation 
in LDL-C reduction with statins. In addition, more than 40% of subjects did not 
achieve targets of <1.8 mmol/L with a fixed statin dose. Those who achieved very 
low levels of LDL-C had a lower event rate than those who achieved modest levels. 
The same trend was seen for non-HDL-C and apo B.
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We will be able to test the “lower is better” hypothesis at very low levels of 
LDL-C when the results of ongoing trials using nonstatins (e.g., inhibitors of 
cholesterol absorption, proprotein convertase subtisilin/kexin type 9 (PCSK9) and 
cholesterol ester transfer protein (CETP) are well established and widely applicable 
to practitioners.
The ACC/AHA guidelines would appear at first blush to support a “fire and 
forget” approach. The text and algorithms do, however, suggest that measuring 
LDL-C after statin initiation is reasonable to help assess compliance and to ensure 
achievement of an expected percentage of decrease of LDL-C. Compliance and 
adherence are important issues with statin therapy [32] and beyond the scope 
of this review, but are certainly another practical reason that the CCS guidelines 
panel continues to recommend targets. Additionally, the text and algorithms of the 
ACC/AHA guidelines promote LDL-C measurement to ensure achievement of the 
expected response to moderate- and high-intensity statin dose choices and, when 
not achieved or in the face of statin intolerance, support dose escalation or addition 
of secondary, non-statin drugs.
The new ACC/AHA guidelines have generated considerable debate and confu-
sion in the medical literature about the specifics of risk assessment and treatment of 
dyslipidemia in cardiovascular disease prevention. It is healthy to accept that there are 
different approaches to screening and management, because of the lack of decisive 
evidence in certain domains. The discussion should be used to highlight the need to 
address outstanding questions in the future. However, in the interim, our patients can 
be very well managed with existing guidelines that are updated on an ongoing basis 
when new knowledge is generated. A guidelines-based approach to screening, treat-
ment, and compliance should continue to be the standard for all of our at-risk patients.
In conclusion, the National Guideline campaigns to increase the awareness 
among both physicians and patients of the importance of achieving the LDL-C 
goals are needed to optimize the prevention of cardiovascular events and to further 
reduce the burden of cardiovascular diseases.
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